srch

Pipeline. BerGenBio is focused on developing a pipeline of transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.

WhatsUp with BerGenBio? [90], 21861, Move Along. 03.12.2021. Forum, Ticker, Siste, Innlegg, Svar, Lest, Av ...

16.12.2021 · Pipeline of first-in-class AXL inhibitors for the treatment of aggressive diseases. BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection.

30.11.2020 · 12.07.2020 · BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONF. 5470 MiniMe 04.03.2021; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 21:40 - E24- Bergenbio ferdige med rekruttering til covid-studie 1435 aibo 03.03.2021; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 18:05: BERGENBIO - VERDIVURDERING - ANALYSER osv …

26.10.2020 · Forum forside Tickerliste Info Logg inn Registrér Alle fora. Farma 01.01 11:11 Shipping 01.01 11:59 Finans og forsikring 01.01 07:58 Innovasjon og Vext 01.01 03:15 Olje og energi 01.01 11:18 Industri 01.01 01:12 Eiendom 01.01 11:33 Handel 31.12 ...

Find the latest BERGENBIO ASA (BRRGF) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Latest News · BERGENBIO ASA: LEADERSHIP CHANGE · BERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN RELAPSED AML ...

Bergen, Norway, 18 May 2021 – BerGenBio ASA (OSE:BGBIO), ... 7th Annual Immuno-Oncology Innovation Forum (SACHS), May 18, 2021.

BERGENBIO PRESENTING AT SACHS 7TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM. Bergen, Norway, 18 May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage ...

Annual Report 2020. BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers. Our annual report.

16.12.2021 · BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB in STK11-mutated advanced/metastatic Non-small cell lung cancer (NSCLC) November 9, 2021. Bergen, Norway, 9 November 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…. Read More.

DN Investor gir deg markedsoversikt og nye spennende verktøy som kan hjelpe deg å få oversikt over finansmarkedene.

BerGenBio: Developing first-in-class AXL inhibitors for aggressive diseases, including advanced, treatment resistant cancers.

Bergenbio : COVID-19 Drug Cuts Death In Mid-Stage Studies | MarketScreener ... artikkelen lenket ovenfor: RE: BGBIO Aksjonæroversikt | Finansavisen Forum.

Yearly Reports. Annual Report 2020. BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, ...

12.07.2020 · Pipeline Bergen bio!! 435 Gullit 21.04.2021; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 13:13: bemcentinib i covid -toplinie viser reduceret dødelighed ! ! ! 6542 Rule 19.04.2021; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 22:23: BGBIO- Hva foregår i Bergen Bio? 10109 focuss Farma: BGBIO 17:45: FINS DET PILLER MOT ...

Kjøp BERGENBIO (BGBIO) aksjen. Hos Nordnet kan du handle fra 1 kr i kurtasje. Klikk her for å følge aksjekursen i realtid

BerGenBio har fortsatt å gjøre fremskritt i testing og kliniske programmer i andre kvartal, men pengene renner ut. tirsdag 27. juli 2021. – Om BerGenBio het OsloBio hadde kursen vært doblet. Trond Mohn tjente 542,5 millioner kroner i fjor, hvor BerGenBio var den viktigste bidragsyteren.